Brivekimig clinical trials
Also written SAR442970.
How each study uses brivekimig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the brivekimig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test brivekimig.
- Dec 2026A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisPhase 2 · Sanofi
- Dec 2026A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseasePhase 2 · Sanofi
- Dec 2026A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseasePhase 2 · Sanofi
- Feb 2027Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaPhase 2 · Sanofi
- Apr 2027Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® MoleculePhase 2 · Sanofi
Studies
Open first, then newest update. How each study uses brivekimig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseRecruitingPhase 2SanofiNCT06500702Written as brivekimig
- A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseRecruitingPhase 2SanofiNCT06958536Written as brivekimig
- Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaRecruitingPhase 2SanofiNCT07170917Written as Brivekimig
- A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisActive, not recruitingPhase 2SanofiNCT06975722Written as SAR442970
- Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® MoleculeActive, not recruitingPhase 2SanofiNCT06812988Written as Brivekimig
- A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis SuppurativaCompletedPhase 2SanofiNCT05849922Written as SAR442970
Codes
What other systems call brivekimig · ClinicalTrials.gg INT018510
- UNII (FDA) XX2BGT8CLLBRIVEKIMIGOne source FDA
- NCI Thesaurus C206890BrivekimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XX2BGT8CLL | BRIVEKIMIG | One source FDA |
| NCI Thesaurus | C206890 | Brivekimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.